These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2497088)

  • 1. Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.
    Cheung NK; Munn D; Kushner BH; Usmani N; Yeh SD
    Int J Rad Appl Instrum B; 1989; 16(2):111-20. PubMed ID: 2497088
    [No Abstract]   [Full Text] [Related]  

  • 2. Iodine 131 labeled GD2 monoclonal antibody in the diagnosis and therapy of human neuroblastoma.
    Cheung NK; Miraldi FD
    Prog Clin Biol Res; 1988; 271():595-604. PubMed ID: 3406022
    [No Abstract]   [Full Text] [Related]  

  • 3. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with GD2 specific monoclonal antibodies.
    Cheung NK; Medof ME; Munn D
    Prog Clin Biol Res; 1988; 271():619-32. PubMed ID: 3043454
    [No Abstract]   [Full Text] [Related]  

  • 5. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-GD2 immunotherapy for neuroblastoma.
    Sait S; Modak S
    Expert Rev Anticancer Ther; 2017 Oct; 17(10):889-904. PubMed ID: 28780888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of high-risk neuroblastoma with anti-GD2 antibodies.
    Castel V; Segura V; Cañete A
    Clin Transl Oncol; 2010 Dec; 12(12):788-93. PubMed ID: 21156409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma.
    Voeller J; Sondel PM
    J Pediatr Hematol Oncol; 2019 Apr; 41(3):163-169. PubMed ID: 30897608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State of the art in immunotherapy of neuroblastoma.
    Jabbari P; Hanaei S; Rezaei N
    Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.
    Perez Horta Z; Goldberg JL; Sondel PM
    Immunotherapy; 2016 Sep; 8(9):1097-117. PubMed ID: 27485082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice.
    Cheung NK; Landmeier B; Neely J; Nelson AD; Abramowsky C; Ellery S; Adams RB; Miraldi F
    J Natl Cancer Inst; 1986 Sep; 77(3):739-45. PubMed ID: 3091900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising therapeutic targets in neuroblastoma.
    Matthay KK; George RE; Yu AL
    Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
    Ahmed M; Cheung NK
    FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell.
    Saito M; Yu RK; Cheung NK
    Biochem Biophys Res Commun; 1985 Feb; 127(1):1-7. PubMed ID: 2579648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcome of adult-onset neuroblastoma.
    Suzuki M; Kushner BH; Kramer K; Basu EM; Roberts SS; Hammond WJ; LaQuaglia MP; Wolden SL; Cheung NV; Modak S
    Int J Cancer; 2018 Sep; 143(5):1249-1258. PubMed ID: 29574715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
    Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the murine anti-Gd-2 antibody 14.Gd-2a for diagnosis and therapy of neuroblastoma.
    Reuland P; Handgretinger R; Smykowsky H; Dopfer R; Klingebiel T; Miller BM; Reisfeld RA; Gallagher S; Koscelniak E; Treuner J
    Int J Rad Appl Instrum B; 1991; 18(1):121-5. PubMed ID: 2010296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.